Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. / Schoos, Mikkel Malby; Kelbæk, Henning; Kofoed, Klaus F; Køber, Lars; Kløvgaard, Lene; Helqvist, Steffen; Engstrøm, Thomas; Saunamäki, Kari; Jørgensen, Erik; Holmvang, Lene; Clemmensen, Peter.

I: American Journal of Cardiology, Bind 107, Nr. 11, 2011, s. 1597-603.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Schoos, MM, Kelbæk, H, Kofoed, KF, Køber, L, Kløvgaard, L, Helqvist, S, Engstrøm, T, Saunamäki, K, Jørgensen, E, Holmvang, L & Clemmensen, P 2011, 'Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention', American Journal of Cardiology, bind 107, nr. 11, s. 1597-603. https://doi.org/10.1016/j.amjcard.2011.01.042

APA

Schoos, M. M., Kelbæk, H., Kofoed, K. F., Køber, L., Kløvgaard, L., Helqvist, S., Engstrøm, T., Saunamäki, K., Jørgensen, E., Holmvang, L., & Clemmensen, P. (2011). Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. American Journal of Cardiology, 107(11), 1597-603. https://doi.org/10.1016/j.amjcard.2011.01.042

Vancouver

Schoos MM, Kelbæk H, Kofoed KF, Køber L, Kløvgaard L, Helqvist S o.a. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. American Journal of Cardiology. 2011;107(11):1597-603. https://doi.org/10.1016/j.amjcard.2011.01.042

Author

Schoos, Mikkel Malby ; Kelbæk, Henning ; Kofoed, Klaus F ; Køber, Lars ; Kløvgaard, Lene ; Helqvist, Steffen ; Engstrøm, Thomas ; Saunamäki, Kari ; Jørgensen, Erik ; Holmvang, Lene ; Clemmensen, Peter. / Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. I: American Journal of Cardiology. 2011 ; Bind 107, Nr. 11. s. 1597-603.

Bibtex

@article{58b30b6234e8452e994fcd089a5eb1c8,

title = "Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention",

abstract = "It is unknown whether high-sensitivity C-reactive protein (hs-CRP) predicts outcome depending on implanted stent type. We investigated the prognostic value of hs-CRP in relation to type of stent implanted in patients with ST-segment elevation myocardial infarction (STEMI). Immediately before primary percutaneous coronary intervention (pPCI), 301 patients had blood drawn. Patients were categorized according to hs-CRP levels and combination of hs-CRP (=2 vs >2 mg/L) and stent type (bare metal stent [BMS] vs drug-eluting stent [DES]). Hs-CRP >2 mg/L (median, hazard ratio 2.7, 95% confidence interval 1.3 to 5.6, p = 0.007) and the combined variable of hs-CRP >2 mg/L and BMS (hazard ratio 2.4, 95% confidence interval 1.2 to 4.5, p = 0.006) independently predicted the composite end point of death and MI at 36-month follow-up. There was a significant interaction (p = 0.006) for hs-CRP and stent type. Survival analysis demonstrated significant differences for occurrence of death and MI: 4.8% in BMS + CRP =2 mg/L, 11.9% in DES + CRP =2 mg/L, 17.6% in DES + CRP >2 mg/L, and 27.9% in BMS + CRP >2 mg/L. None of the 14 stent thromboses occurred in patients with BMS + CRP =2 mg/L. In conclusion, preprocedure hs-CRP predicts outcome after pPCI in patients with STEMI. Our hypothesis-generating data indicate that BMS implantation should be preferred when hs-CRP is =2 mg/L and DES when hs-CRP is >2 mg/L to decrease long-term adverse outcomes including stent thrombosis in patients with STEMI treated with pPCI. These findings need confirmation in larger randomized clinical trials.",

author = "Schoos, {Mikkel Malby} and Henning Kelb{\ae}k and Kofoed, {Klaus F} and Lars K{\o}ber and Lene Kl{\o}vgaard and Steffen Helqvist and Thomas Engstr{\o}m and Kari Saunam{\"a}ki and Erik J{\o}rgensen and Lene Holmvang and Peter Clemmensen",

year = "2011",

doi = "http://dx.doi.org/10.1016/j.amjcard.2011.01.042",

language = "English",

volume = "107",

pages = "1597--603",

journal = "Am. J. Cardiol.",

issn = "0002-9149",

publisher = "Elsevier",

number = "11",

}

RIS

TY - JOUR

T1 - Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention

AU - Schoos, Mikkel Malby

AU - Kelbæk, Henning

AU - Kofoed, Klaus F

AU - Køber, Lars

AU - Kløvgaard, Lene

AU - Helqvist, Steffen

AU - Engstrøm, Thomas

AU - Saunamäki, Kari

AU - Jørgensen, Erik

AU - Holmvang, Lene

AU - Clemmensen, Peter

PY - 2011

Y1 - 2011

N2 - It is unknown whether high-sensitivity C-reactive protein (hs-CRP) predicts outcome depending on implanted stent type. We investigated the prognostic value of hs-CRP in relation to type of stent implanted in patients with ST-segment elevation myocardial infarction (STEMI). Immediately before primary percutaneous coronary intervention (pPCI), 301 patients had blood drawn. Patients were categorized according to hs-CRP levels and combination of hs-CRP (=2 vs >2 mg/L) and stent type (bare metal stent [BMS] vs drug-eluting stent [DES]). Hs-CRP >2 mg/L (median, hazard ratio 2.7, 95% confidence interval 1.3 to 5.6, p = 0.007) and the combined variable of hs-CRP >2 mg/L and BMS (hazard ratio 2.4, 95% confidence interval 1.2 to 4.5, p = 0.006) independently predicted the composite end point of death and MI at 36-month follow-up. There was a significant interaction (p = 0.006) for hs-CRP and stent type. Survival analysis demonstrated significant differences for occurrence of death and MI: 4.8% in BMS + CRP =2 mg/L, 11.9% in DES + CRP =2 mg/L, 17.6% in DES + CRP >2 mg/L, and 27.9% in BMS + CRP >2 mg/L. None of the 14 stent thromboses occurred in patients with BMS + CRP =2 mg/L. In conclusion, preprocedure hs-CRP predicts outcome after pPCI in patients with STEMI. Our hypothesis-generating data indicate that BMS implantation should be preferred when hs-CRP is =2 mg/L and DES when hs-CRP is >2 mg/L to decrease long-term adverse outcomes including stent thrombosis in patients with STEMI treated with pPCI. These findings need confirmation in larger randomized clinical trials.

AB - It is unknown whether high-sensitivity C-reactive protein (hs-CRP) predicts outcome depending on implanted stent type. We investigated the prognostic value of hs-CRP in relation to type of stent implanted in patients with ST-segment elevation myocardial infarction (STEMI). Immediately before primary percutaneous coronary intervention (pPCI), 301 patients had blood drawn. Patients were categorized according to hs-CRP levels and combination of hs-CRP (=2 vs >2 mg/L) and stent type (bare metal stent [BMS] vs drug-eluting stent [DES]). Hs-CRP >2 mg/L (median, hazard ratio 2.7, 95% confidence interval 1.3 to 5.6, p = 0.007) and the combined variable of hs-CRP >2 mg/L and BMS (hazard ratio 2.4, 95% confidence interval 1.2 to 4.5, p = 0.006) independently predicted the composite end point of death and MI at 36-month follow-up. There was a significant interaction (p = 0.006) for hs-CRP and stent type. Survival analysis demonstrated significant differences for occurrence of death and MI: 4.8% in BMS + CRP =2 mg/L, 11.9% in DES + CRP =2 mg/L, 17.6% in DES + CRP >2 mg/L, and 27.9% in BMS + CRP >2 mg/L. None of the 14 stent thromboses occurred in patients with BMS + CRP =2 mg/L. In conclusion, preprocedure hs-CRP predicts outcome after pPCI in patients with STEMI. Our hypothesis-generating data indicate that BMS implantation should be preferred when hs-CRP is =2 mg/L and DES when hs-CRP is >2 mg/L to decrease long-term adverse outcomes including stent thrombosis in patients with STEMI treated with pPCI. These findings need confirmation in larger randomized clinical trials.

U2 - http://dx.doi.org/10.1016/j.amjcard.2011.01.042

DO - http://dx.doi.org/10.1016/j.amjcard.2011.01.042

M3 - Journal article

VL - 107

SP - 1597

EP - 1603

JO - Am. J. Cardiol.

JF - Am. J. Cardiol.

SN - 0002-9149

IS - 11

ER -

ID: 40147192